Product Wiki · Recalls · EU Safety Gate (RAPEX)

Lazell blue day — recall A12/00147/23

EU Safety Gate (RAPEX) · Czechia · 2023-01-27 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/00147/23
Date of alert
2023-01-27
Country / jurisdiction
Czechia
Risk level
Serious risk
Risk type
Chemical
Brand
Lazell Parfums
Product category
Cosmetics
Product type
Eau de parfum
Barcode (EAN/GTIN)
5907176583076
Reported risk: Produkt obsahuje nadměrnou koncentraci citralu (naměřená hodnota až 0,028 % hmotnosti). Citral způsobuje podráždění kůže a může způsobit alergickou kožní reakci. Produkt není v souladu s nařízením o kosmetických přípravcích.
Action taken by the authority
Type of economic operator to whom the measure were ordered
Retailer
Category of measure
Withdrawal of the product from the market
Date of entry into force
06/01/2023
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): Lazell blue day

Risk Description (original English): The product contains an excessive concentration of citral (measured value up to 0.028 % by weight). Citral causes skin irritation and may cause an allergic skin reaction.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10007641

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.